Tempus AI (NASDAQ:TEM) Stock Keeps Buy Rating at BTIG Research

Tempus AI (NASDAQ:TEM)‘s stock had its “buy” rating restated by research analysts at BTIG Research in a report released on Monday, Benzinga reports. They presently have a $80.00 target price on the stock. BTIG Research‘s price target indicates a potential upside of 21.79% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. Stifel Nicolaus reduced their target price on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a report on Monday, August 3rd. The Goldman Sachs Group began coverage on shares of Tempus AI in a research report on Monday, September 21st. They set a “neutral” rating and a $75.00 price target on the stock. Raymond James Financial set a $80.00 price target on shares of Tempus AI in a research report on Wednesday, September 2nd. Piper Sandler raised shares of Tempus AI from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $56.00 to $76.00 in a research note on Tuesday, September 1st. Finally, Roth Capital started coverage on Tempus AI in a report on Tuesday, September 8th. They set a “neutral” rating and a $67.00 price objective on the stock. Eleven investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $72.47.

Tempus AI Stock Down 2.8%

Shares of TEM stock opened at $65.69 on Monday. The company has a market capitalization of $11.85 billion, a price-to-earnings ratio of -45.58 and a beta of 3.54. The company’s fifty day moving average price is $69.24 and its 200-day moving average price is $57.26. Tempus AI has a one year low of $40.77 and a one year high of $93.38. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16.

Tempus AI (NASDAQ:TEM) last released its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative net margin of 17.77% and a negative return on equity of 50.28%. The firm had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. During the same quarter last year, the business earned ($0.22) EPS. The business’s revenue was up 21.6% on a year-over-year basis. Sell-side analysts expect that Tempus AI will post -1.43 EPS for the current fiscal year.

Insider Activity

In other news, EVP Andrew Polovin sold 22,148 shares of the firm’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $1,098,762.28. Following the completion of the transaction, the executive vice president directly owned 146,067 shares of the company’s stock, valued at approximately $7,246,383.87. This trade represents a 13.17% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 41,095 shares of Tempus AI stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $2,038,722.95. Following the transaction, the chief executive officer directly owned 562,463 shares of the company’s stock, valued at $27,903,789.43. This represents a 6.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 1,280,965 shares of company stock worth $80,397,564 in the last 90 days. Insiders own 24.26% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Guardian Partners Inc. raised its holdings in Tempus AI by 8.3% in the third quarter. Guardian Partners Inc. now owns 2,600 shares of the company’s stock worth $213,000 after purchasing an additional 200 shares in the last quarter. V Square Quantitative Management LLC purchased a new stake in shares of Tempus AI in the third quarter worth about $27,000. Cyndeo Wealth Partners LLC boosted its position in Tempus AI by 6.7% during the third quarter. Cyndeo Wealth Partners LLC now owns 6,412 shares of the company’s stock worth $525,000 after purchasing an additional 400 shares in the last quarter. Arkadios Wealth Advisors lifted its position in shares of Tempus AI by 9.6% in the first quarter. Arkadios Wealth Advisors now owns 4,963 shares of the company’s stock valued at $224,000 after acquiring an additional 435 shares in the last quarter. Finally, GAMMA Investing LLC boosted its position in shares of Tempus AI by 54.3% during the third quarter. GAMMA Investing LLC now owns 1,239 shares of the company’s stock worth $101,000 after buying an additional 436 shares during the period. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus AI, Inc is a healthcare technology company that uses artificial intelligence and data analytics to support precision medicine. The company combines clinical, molecular and imaging data to help physicians make more informed treatment decisions and to help researchers and biopharmaceutical companies develop therapies.

Its offerings include genomic testing and analysis, such as tissue- and blood-based tests, as well as software tools designed to assist with clinical decision-making, patient matching for clinical trials and the management of healthcare data.